Harvard Catalyst Profiles

Contact, publication, and social network information about Harvard faculty and fellows.

Rifaquat Musaffa Rahman, M.D.

Concepts

This page shows the publications Rifaquat Rahman has written about Brain Neoplasms.
Connection Strength

1.278
  1. Neurologic Complications of Cranial Radiation Therapy and Strategies to Prevent or Reduce Radiation Toxicity. Curr Neurol Neurosci Rep. 2020 06 29; 20(8):34.
    View in: PubMed
    Score: 0.204
  2. Prediction of Outcomes with a Computational Biology Model in Newly Diagnosed Glioblastoma Patients Treated with Radiation Therapy and Temozolomide. Int J Radiat Oncol Biol Phys. 2020 11 01; 108(3):716-724.
    View in: PubMed
    Score: 0.202
  3. The impact of timing of immunotherapy with cranial irradiation in melanoma patients with brain metastases: intracranial progression, survival and toxicity. J Neurooncol. 2018 Jun; 138(2):299-306.
    View in: PubMed
    Score: 0.173
  4. Incidence, risk factors, and reasons for hospitalization among glioblastoma patients receiving chemoradiation. J Neurooncol. 2015 Aug; 124(1):137-46.
    View in: PubMed
    Score: 0.143
  5. Retrospective study of carmustine or lomustine with bevacizumab in recurrent glioblastoma patients who have failed prior bevacizumab. Neuro Oncol. 2014 Nov; 16(11):1523-9.
    View in: PubMed
    Score: 0.134
  6. Histogram analysis of apparent diffusion coefficient within enhancing and nonenhancing tumor volumes in recurrent glioblastoma patients treated with bevacizumab. J Neurooncol. 2014 Aug; 119(1):149-58.
    View in: PubMed
    Score: 0.133
  7. The effects of releasing early results from ongoing clinical trials. Nat Commun. 2021 02 05; 12(1):801.
    View in: PubMed
    Score: 0.053
  8. Immune checkpoint inhibitor therapy may increase the incidence of treatment-related necrosis after stereotactic radiosurgery for brain metastases: a systematic review and meta-analysis. Eur Radiol. 2021 Jun; 31(6):4114-4129.
    View in: PubMed
    Score: 0.052
  9. Quantitative imaging biomarkers for risk stratification of patients with recurrent glioblastoma treated with bevacizumab. Neuro Oncol. 2017 Nov 29; 19(12):1688-1697.
    View in: PubMed
    Score: 0.043
  10. Multimodal imaging patterns predict survival in recurrent glioblastoma patients treated with bevacizumab. Neuro Oncol. 2016 12; 18(12):1680-1687.
    View in: PubMed
    Score: 0.038
  11. The Impact of T2/FLAIR Evaluation per RANO Criteria on Response Assessment of Recurrent Glioblastoma Patients Treated with Bevacizumab. Clin Cancer Res. 2016 Feb 01; 22(3):575-81.
    View in: PubMed
    Score: 0.037
  12. Spin-echo echo-planar perfusion prior to chemoradiation is a strong independent predictor of progression-free and overall survival in newly diagnosed glioblastoma. J Neurooncol. 2014 Aug; 119(1):111-9.
    View in: PubMed
    Score: 0.033
  13. Recurrent glioblastoma: volumetric assessment and stratification of patient survival with early posttreatment magnetic resonance imaging in patients treated with bevacizumab. Cancer. 2013 Oct 01; 119(19):3479-88.
    View in: PubMed
    Score: 0.031
Connection Strength

The connection strength for concepts is the sum of the scores for each matching publication.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.

Funded by the NIH National Center for Advancing Translational Sciences through its Clinical and Translational Science Awards Program, grant number UL1TR002541.